Associated Papers
R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancers.
Zhang C et al.
Nature Communications, 2026
BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability.
Situ K et al.
Nature Communications, 2025
Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression.
Chen C et al.
Journal for Immunotherapy of Cancer, 2022
36323433 (PubMed )
Supplement: jitc-2022-005503supp001.pdf
Active site plasticity and possible modes of chemical inhibition of the human DNA deaminase APOBEC3B.
Shi K et al.
Faseb Bioadvances, 2020
APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
Ma W et al.
Molecular Carcinogenesis, 2019
APOBEC3 induces mutations during repair of CRISPR-Cas9-generated DNA breaks.
Lei L et al.
Nature Structural & Molecular Biology, 2018
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Law EK et al.
Science Advances, 2016
A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
Caval V et al.
Nature Communications, 2014
Repair of naturally occurring mismatches can induce mutations in flanking DNA.
Chen J et al.
Elife, 2014
D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B.
McDougle RM et al.
Virology, 2013
APOBEC3B is an enzymatic source of mutation in breast cancer.
Burns MB et al.
Nature, 2013
APOBEC3B and AID have similar nuclear import mechanisms.
Lackey L et al.
Journal of Molecular Biology, 2012
Select a paper to view details